Michael Hunkapiller In, Hugh Martin Out as CEO of Pacific Biosciences | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences today announced Michael Hunkapiller is replacing Hugh Martin as the company's president and CEO, effective immediately.

Martin will remain on the company's board of directors through its next annual meeting of shareholders and has agreed to resign from the board on the date of the meeting. He will serve as a consultant to PacBio for six months, it said in a document filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.